SOHO 2022 | Novel treatment approaches in BPDCN: the promise of CD123-targeting allogeneic CAR-T cells
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York, NY, discusses novel treatment approaches for blastic plasmacytoid dendritic cell neoplasm (BPDCN), drawing focus on the promise of CD123-targeting agents. Prof. Konopleva first comments on the approval of tagraxofusp in BPDCN and the efficacy of this agent, and then goes on to explain the role of CAR-T cells in this space. To conclude, Prof. Konopleva shares some insights into a pre-clinical study evaluating CD123-targeting allogeneic CAR-T cells in BPDCN, and the impact that these agents may have on the BPDCN treatment landscape. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
